In 2011 Transdel filed for a petition for reorganization under chapter 11 in Bankruptcy court. This timeline coincides with when Mark Baum was brought on as CEO; also 2011. Baum saw the company through the restructuring that year and they requested the court to dismiss the chapter 11 in November 2011. In Feb 2012, they changed their name to Imprimis.
I believe the company than seized the opportunity of compounding pharma on the passing of the Drug Quality and Security Act of 2013 which was put in place to employ strict guidance and oversight in the compounding pharmacy industry.